Preventing Premature Weaning: Management Options for Common Lactation Conditions, Including OMT

2020 ◽  
pp. 20-25
Author(s):  
Denise Sackett ◽  
Tala Dajani ◽  
David Shoup ◽  
Uzoma Ikonne
Keyword(s):  
Postpartum Depression ◽  
Family Physician ◽  
Treatment Options ◽  
World Health ◽  
Management Options ◽  
Pharmacological Management ◽  
Control And Prevention ◽  
Lactational Mastitis ◽  
One Year ◽  
Health Organization

The benefits of breastfeeding are well established. The World Health Organization and the Centers for Disease Control and Prevention recommend that mothers breastfeed infants for at least one year, but most children are not breastfed that long because of many factors. Breastfeeding mothers face many challenges to continued breastfeeding, including medical conditions that arise during this period, such as postpartum depression and lactational mastitis. Because of a perceived lack of consistent guidance on medication safety, it can be difficult for the family physician to treat these conditions while encouraging mothers to continue breastfeeding. The purpose of the current review is to summarize and clarify treatment options for the osteopathic family physician treating lactating mothers. We specifically focus on the pharmacological management of contraception, postpartum depression, and lactational mastitis.

scholarly journals INFERTILITY MANAGEMENT THROUGH AYURVEDA SHODHANA KARMA- A CASE REPORT

2019 ◽  
pp. 171-173
Author(s):  
Pooja .S. Dhuria ◽  
Prathima
Keyword(s):  
Treatment Options ◽  
Female Infertility ◽  
Reproductive Age ◽  
World Health ◽  
Clinical Feature ◽  
Traditional System ◽  
The World ◽  
One Year ◽  
Health Organization ◽  
Consecutive Cycle

Purpose: The World Health Organization (WHO) estimate that 60 to 80 million couples worldwide currently suffer from infertility. The female infertility has becomes major issue in current scenario due to the increasing number of incidences day by day. In India alone many couples suffers from infertility. The treatment options of female infertility also improving and traditional system of medicine such as Ayurveda describes female infertility broadly with its treatment protocol.Infertility affects women of reproductive age group all over the world. The infertility can be primary or secondary. Panchakarma can treat infertility successfully using various methods along with Ayurvedic formulations. Methodology: A Female Patient of 26 year came to OPD presenting with the complaints of inability to Conceive. Patient was complaining of delayed and heavy menstrual Periods as a clinical feature of PCOD which was diagnosed in USG report Patient was treated with Panchakarma and Ayurvedic Oral medicine. Vamana karma was done and in next Consecutive Cycle Patient got conceived. Result: In next Consecutive Cycle Patient got conceived and she is under regular Antenatal check up. Conclusion: Infertility is defined as a failure to conceive within one year or more years of regular unprotected coitus. PCOD occurs due to an imbalance caused by any of the three Doshas which affect the fertility of the female. These causes increase of Kapha and Vata Dosha and cause the formation of the multiple cysts in ovaries leading to anovulatory periods followed by obesity, hirustitsm. Vamana Karma helps in Strotoshudhi and help in the kapha disorders. Pushpadhanwa rasa act on the Manashanthi and Garbhakrut. Ashwagandha Ksheerpaka acts as Garbhasthapaka and Rasayana. The present study reveals the effective management of infertility associated with PCOD was managed by Shodana and Garbhasthapaka oushadhi KEYWORDS: PCOS, Artava Dusti ,Sthoulya, Infertility

scholarly journals Candidates for treatment of COVID-19: current scenario and way forwards

2020 ◽  
Vol 7 (8) ◽  
pp. 3273
Author(s):  
M. Abu Bashar
Keyword(s):  
Clinical Efficacy ◽  
Clinical Characteristics ◽  
Treatment Options ◽  
Therapeutic Agents ◽  
World Health ◽  
Current Evidence ◽  
Efficacy And Safety ◽  
Control And Prevention ◽  
Current Scenario ◽  
Health Organization

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic affecting 215 countries. At the time of this review, COVID-19 has been diagnosed in more than 15,000,000 patients and associated with over 1,00,000 deaths globally (Centers for Disease Control and Prevention, World Health Organization). In this review, we herein summarize the current evidence as on May 15, 2020 to provide guidance on potentially beneficial drugs in COVID-19 treatment or prophylaxis, their scientific rationale and their clinical efficacy and safety. New data continue to emerge daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for many potential therapeutic agents is still under investigation.

scholarly journals COVID-19 ‘The Pandemic’: An Update on the Present Status of the Outbreak and Possible Treatment Options

2020 ◽  
Vol 13 (4) ◽  
pp. 1791-1807
Author(s):  
Deepika Purohit ◽  
Manisha Saini ◽  
Nisha Pathak ◽  
Ravinder Verma ◽  
Deepak Kaushik ◽  
...  
Keyword(s):  
Present Status ◽  
Preventive Measures ◽  
Treatment Options ◽  
Review Literature ◽  
World Health ◽  
Control And Prevention ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Associated Risk Factors ◽  
Global Threat

A novel threat to mankind by novel coronavirus infection occurred in December 2019. According to the World Health Organization (WHO) Situation Report-141, 7,039,918 confirmed cases and 404,396 death cases were observed till 9 June 2020 in the different regions of world. Therefore, this article aims to summarize and share the update on the present status of the outbreak and possible treatment options. The present review focuses on latest statistics, diagnostic and preventive measures under study and the future planning of the researchers to discover an effective cure for this threat to the mankind. For carrying out this review, literature searches were performed on Clinicaltrials.gov, official website of WHO, Centers for Disease Control and Prevention, PubMed, Google scholars, etc. Data from these searches was collected and evaluated for getting the available literature on COVID-19 outbreak and drugs under study. The details of history, virology, epidemiology, possible therapeutic options, associated risk factors and preventive measures related to COVID-19 are compiled here in this review. Along with this, some ongoing clinical trials have also been included in this review in order to conclude the efforts of researchers towards controlling this outbreak. The trajectory and severity of this outbreak can’t be predicted at present, but immediate actions are required to be taken in order to develop and implement an effective treatment against the global threat.

scholarly journals Candidates for Treatment of Novel Corona virus disease, COVID-19: Current Scenario and Way Forwards

2021 ◽  
Vol 2 (1) ◽  
pp. 01-04
Author(s):  
Abu Bashar
Keyword(s):  
Clinical Efficacy ◽  
Virus Disease ◽  
Treatment Options ◽  
Therapeutic Agents ◽  
World Health ◽  
Current Evidence ◽  
Efficacy And Safety ◽  
Control And Prevention ◽  
Current Scenario ◽  
Health Organization

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic affecting 215 countries. At the time of this review, COVID-19 has been diagnosed in more than 15,000,000 patients and associated with over 1,00,000 deaths globally (Canters for Disease Control and Prevention, World Health Organization). In this review, we herein summarize the current evidence as on June 15, 2020 to provide guidance on potential drugs for COVID-19 treatment or prophylaxis, their scientific rationale and their clinical efficacy and safety. New data continue to emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the potential therapeutic agents is still under investigation.

scholarly journals Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options

2020 ◽  
Vol 7 (4) ◽  
Author(s):  
Erin K McCreary ◽  
Jason M Pogue
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Infectious Diseases ◽  
Supportive Care ◽  
Emergency Preparedness ◽  
Clinical Characteristics ◽  
Treatment Options ◽  
World Health ◽  
Current Evidence ◽  
Control And Prevention ◽  
Health Organization

Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has spread across the globe resulting in a pandemic. At the time of this review, COVID-19 has been diagnosed in more than 200 000 patients and associated with over 8000 deaths (Centers for Disease Control and Prevention, World Health Organization). On behalf of the Society of Infectious Diseases Pharmacists, we herein summarize the current evidence as of March 18, 2020 to provide guidance on potential COVID-19 treatment options. It is important to caution readers that new data emerges daily regarding clinical characteristics, treatment options, and outcomes for COVID-19. Optimized supportive care remains the mainstay of therapy, and the clinical efficacy for the subsequent agents is still under investigation. Antimicrobial stewardship programs, including infectious diseases pharmacists and physicians, are at the forefront of COVID-19 emergency preparedness. We encourage all readers to continue to assess clinical data as it emerges and share their experience within our community in a well-controlled, adequately powered fashion.

scholarly journals Third wave of Covid -19 in Pakistan: New Variants with new travelers?

2021 ◽  
pp. 03
Author(s):  
Naveed Akhtar ◽  
Sara Hayee ◽  
Faheem Nawaz ◽  
Muhammad Idnan
Keyword(s):  
World Health ◽  
Border Crossings ◽  
Third Wave ◽  
First Case ◽  
Positive Rate ◽  
Control And Prevention ◽  
Current Outbreak ◽  
One Year ◽  
Health Organization ◽  
The Uk

Coronavirus disease (Covid-19) caused by SARS-CoV-2 first experienced in Wuhan city, China during late December 2019, has now spread in 2019 countries and territories including Pakistan. According to World Health Organization (WHO), 125,425,270 confirmed cases with 2,756,679 deaths have been reported till date with highest positive cases encountered in USA followed by Brazil and India. Pakistan, a developing country in the Asia, faces a big challenge with Covid-19. In Pakistan, the first case of the Coronavirus disease (Covid-19) was reported on February 26, 2020 by Ministry of Health, Government of Pakistan in Karachi, Sindh. The positive cases reported from Pakistan had travel history from Iran, London and Syria. The rapid rise of the positive cases of Covid 19 in first wave in Pakistan is attributed to mishandling of the pilgrims coming from Iran through Taftan, one of Pakistan’s border crossings with Iran. Also, the students in China were returning back to Pakistan especially from the Wuhan, which is the site of the origin of the Covid-19. With the emergence of the Covid-19, multiple variants of the virus are circulating globally especially B117 virus which is considered more contagious. It is also categorized among Variant of Concern (VOC) by SARS-CoV-2 Interagency Group (SIG) developed Center for Disease Control and Prevention (CDC). After one year, the third wave of Covid-19 has rising throughout the country with maximum positive cases of UK variant of SARS-CoV-2. The first case of the Covid-19 with UK strain reported in Pakistan on December 28, 2020 from passengers returning back to Pakistan from United  Kingdom. At least three Covid-19 cases were detected among returnees from the UK, in the southern port city of Karachi, as reported by  the provincial Health Ministry of Pakistan. The UK strain cases were mostly being found among people returning from abroad. The current outbreak of cases is centred around Punjab province, where the tested-positive rate was 17 % in the provincial capital Lahore and 15 % in Rawalpindi and Faisalabad, according to official data. Due to poor health infrastructure and slow vaccination administration in developing countries, there is ample need of policies re-examined especially for international travelling to find the loopholes contributing to next wave of Covid-19 in Pakistan.

Treatment Options in COVID-19: The Role of Bioavailable Antiviral Ribonucleoside Analog on NHC in vitro

2020 ◽  
Author(s):  
Lara Bittmann
Keyword(s):  
World Health Organization ◽  
Clinical Picture ◽  
Treatment Options ◽  
World Health ◽  
Wuhan City ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization

On December 31, 2019, WHO was informed of cases of pneumonia of unknown cause in Wuhan City, China. A novel coronavirus was identified as the cause by Chinese authorities on January 7, 2020 and was provisionally named "2019-nCoV". This new Coronavirus causes a clinical picture which has received now the name COVID-19. The virus has spread subsequently worldwide and was explained on the 11th of March, 2020 by the World Health Organization to the pandemic.

scholarly journals COVID-19 PANDEMIC UPDATES AND PERSPECTIVES. NEED FOR AN INTEGRATED AND EQUITABLE APPROACH.

2021 ◽  
Author(s):  
Grigoris Gerotziafas ◽  
Mariella Catalano ◽  
Ioannis Theodorou ◽  
Patrick van Dreden ◽  
Vincent Marechal ◽  
...  
Keyword(s):  
Mitigation Strategies ◽  
World Health ◽  
Learning Technology ◽  
Pharmacological Interventions ◽  
Health Crisis ◽  
Patients At Risk ◽  
Physical Barriers ◽  
Risk Of Disease ◽  
One Year ◽  
Health Organization

One year after the declaration of the COVID-19 pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing, humanity remains challenged by a long-lasting and devastating public health crisis. Non-pharmacological interventions (NPI) are efficient mitigation strategies. The success of these intense NPI is dependent on the approval and commitment of the population. The launch of a mass vaccination program in many countries in late December 2020 with mRNA vaccines, adenovirus-based vaccines, and inactivated virus vaccines has generated hope for the end of the pandemic. Current issues: The continuous appearance of new pathogenic viral strains and the ability of vaccines to prevent infection and transmission raise important concerns as we try to achieve community immunity against SARS-CoV-2 and its variants. The need of a second and even third generation of vaccines and the possibility of potentially harmful side-effects of the vaccines (i.e. venous thromboembolism ) have already been acknowledged. Perspectives: There is a critical and urgent need for a balanced and integrated strategy for the management of the COVID-19 outbreaks organized on three axes: (1) Prevention of the SARS-CoV-2 infection, (2) Detection and early diagnosis of patients at risk of disease worsening, and (3) Anticipation of medical care (PDA). Conclusion: The “PDA strategy” integrated into state policy for the support and expansion of health systems and introduction of digital organization (i.e. telemedicine, artificial intelligence and machine learning technology) is of major importance for the preservation of citizens’ health and life world-wide.

Fatmisia and Clinical Counseling Decision-Making in Master’s-Level Counselor Trainees

2021 ◽  
Vol 43 (4) ◽  
pp. 336-353
Author(s):  
Kaitlyn M. Forristal ◽  
John M. Laux ◽  
Madeline Clark ◽  
Jennifer L. Reynolds ◽  
Taylor M. Nelson
Keyword(s):  
Short Form ◽  
Counselor Trainees ◽  
World Health ◽  
Master's Level ◽  
Clinical Counseling ◽  
Control And Prevention ◽  
Weight Bias Internalization ◽  
Fat Phobia ◽  
Health Organization ◽  
The Relationship

The Centers for Disease Control and Prevention and the World Health Organization have documented an increase in fat people in recent decades, which is being met with a backlash of anti-fat biases, or fatmisia. Fatmisia is prevalent in most aspects of society, especially among fat people who have internalized fatmisia. Utilizing a diagnostic questionnaire in combination with the Fat Phobia Scale–Short Form and the Weight Bias Internalization Scale, this study explored the relationship between client body size, the presence of a major depressive disorder (MDD) diagnosis, and if applicable, the severity of MDD symptoms assigned by counselor trainees (N = 113). Results were analyzed using one-way analysis of variance and covariance. This sample (N = 113) significantly differed in diagnoses assigned to obese clients by assigning more severe MDD. Study limitations and implications are discussed.

scholarly journals Impact of External Quality Assurance on the Quality of Xpert MTB/RIF Testing in Viet Nam

2018 ◽  
Vol 57 (3) ◽  
Author(s):  
Vidyanidhi Gumma ◽  
Kyle DeGruy ◽  
Davara Bennett ◽  
Thanh Nguyen Thi Kim ◽  
Heidi Albert ◽  
...  
Keyword(s):  
Quality Assurance ◽  
Positive Impact ◽  
Production Capacity ◽  
Control Program ◽  
External Quality Assurance ◽  
World Health ◽  
External Quality ◽  
National Tuberculosis ◽  
Control And Prevention ◽  
Health Organization

ABSTRACT Following the endorsement of the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) by the World Health Organization (WHO) in 2010, Viet Nam’s National Tuberculosis Control Program (NTP) began using GeneXpert instruments in NTP laboratories. In 2013, Viet Nam’s NTP implemented an Xpert MTB/RIF external quality assurance (EQA) program in collaboration with the U.S. Centers for Disease Control and Prevention (CDC) and the Foundation for Innovative New Diagnostics (FIND). Proficiency-testing (PT) panels comprising five dried tube specimens (DTS) were sent to participating sites approximately twice a year from October 2013 to July 2016. The number of enrolled laboratories increased from 22 to 39 during the study period. Testing accuracy was assessed by comparing reported and expected results; percentage scores were assigned; and feedback reports were provided to sites. On-site evaluation (OSE) was conducted for underperforming laboratories. The results from the first five rounds demonstrate the positive impact of PT and targeted OSE visits on testing quality. On average, for every additional round of feedback, the odds of achieving PT scores of ≥80% increased 2.04-fold (95% confidence interval, 1.39- to 3.00-fold). Future work will include scaling up PT to all sites and maintaining the performance of participating laboratories while developing local panel production capacity.

Sign in / Sign up

Export Citation Format

Share Document